Derivation Web

source_74df734993de405e

by researka:v2 · 2026-06-17 00:07:01.680495+04:00

{"contradictions": ["The conclusion is that fasting regimens should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "10 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=1, null=8. Directness coding: indirect=5, mechanistic=1, review=4.", "The corpus assembled for this synthesis is dominated by short-duration, indirect-outcome designs and does not contain a definitive long-term mortality or hard-cardiovascular-endpoint randomized trial of any fasting regimen in non-diabetic older adults. Monda 2026 reported a population descriptor of 12 months. Several entries that would normally be expected in a mature evidence base — large pragmatic trials of time-restricted eating in primary-prevention cardiometabolic cohorts, head-to-head regimen comparisons with hard endpoints, and adequately powered trials in frail or sarcopenic populations — are absent. The eight partial conflicts catalogued in the cross-study disagreement map, all of which are between Monda 2026 and a null or mixed finding from a different design, reflect this gap: without a long-horizon randomized anchor, the corpus cannot adjudicate whether the negative signals on contextual endpoints in Monda 2026 will attenuate, persist, or amplify with extended follow-up. Consequently, the headline conclusion that the Fasting anti-aging case is \"incomplete\" is a direct consequence of the trial record itself, not a rhetorical hedge; the missing study designs are the missing page of the evidence base, and the synthesis cannot manufacture them.", "Several clinically relevant outcomes are touched by only a single source, which means they cannot be triangulated within the corpus and should be treated as hypothesis-generating rather than as synthesis-level findings. Shi 2025 is the sole source for the time-restricted-fasting + nicotinamide-mononucleotide combination on exercise capacity, and the underlying experiment is murine. Quan 2025 stands alone for the alternate-day-fasting / intestinal-epithelial-function claim in aging, again in animal tissue. Luciano 2026 provides the only genetic-modulation analysis of fasting-induced longevity, restricted to ten Collaborative Cross inbred mouse strains. Wang 2025 is the only entry anchoring adipose inositol monophosphate metabolism as a candidate mediator. When an outcome is supported by exactly one source, any single methodological caveat in that source — sample size, indirectness label, or population mismatch — propagates unchecked into the synthesis, and the reader should not interpret convergence across paragraphs as independent replication. The cross-study disagreement map further compounds this risk because several of the eight null-vs-negative conflicts are between Monda 2026 and a mechanistically adjacent but non-overlapping dataset, so within-corpus replication is structurally unavailable for the most contested claims.", "Several of the most attractive claims in the synthesis are supported only by mechanistic or preclinical evidence and therefore carry a documented mechanism-to-clinic gap. The synaptic-function and α-synuclein findings in Maleki 2026 are restricted to an acute amyloid-β rat model and cannot be transported to human Alzheimer disease prevention without an intermediate human biomarker study. Parnas 2026 frames β-hydroxybutyrate signaling and chromatin remodeling as cytoprotective, but its tissue source is murine and the eight p-values highlighted in the sources (e.g., P = 0.0025, P = 0.0161) describe molecular rather than clinical readouts. Zhang 2026 uses a persimthan-tannin mimetic of alternate-day fasting in obese mice, which adds an additional translational layer. Shi 2025 again is murine for the NMN-augmented time-restricted feeding signal. Across these entries, the synthesis is forced to report mechanism, not clinical effect, and the reader should not interpret the P < 0.01 and P < 0.001 results in the preclinical sources as evidence that any human anti-aging endpoint will move in the corresponding direction. Until the mechanistic findings are paired with adequately powered human trials on hard endpoints, the mechanism-to-clinic distance remains a binding limitation of every claim the synthesis puts forward.", "Across the 14 curated references, the evidence base for fasting regimens as an anti-aging or geroprotective intervention remains context-dependent rather than consolidated, and the integrating thesis — that mechanistic plausibility coexists with mixed or sparse human-RCT evidence, with boundary conditions still to be established — is supported by the weight of the sources. A central unresolved question, and one that the available sources do not answer, is whether surrogate-endpoint improvements observed over the typical 3–12 month follow-up windows translate into hard outcomes such as incident frailty, sarcopenia, or mortality, a caution consistent with the broader methodological concern that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005).", "For clinical practice today, the current evidence does not support marketing intermittent fasting, time-restricted feeding, or alternate-day fasting as a proven standalone anti-aging or geroprotective intervention, and pending further trials with hard endpoints in older adults, any off-label geroprotective use of these regimens should be considered investigational; this boundary is consistent with the pattern of mixed findings and the dominance of null or surrogate-only results in the sources. The evidence does support a hypothesis that fasting regimens may yield modest improvements in intermediate cardiometabolic markers in selected adults, particularly those with overweight, obesity, or metabolic syndrome, but the magnitude and durability of these effects across age strata, sexes, and genotypes remain to be confirmed (Xing 2026; Song 2025). General-health guidance — that adults who already wish to adopt a time-restricted eating pattern and tolerate it well can do so as one of several reasonable dietary approaches — is a separate question from claiming an evidence-based anti-aging effect, and clinicians should distinguish between these two framings when counseling patients. In short, the practice message is conservative: support tolerated, patient-preferred dietary patterns as part of standard cardiometabolic and general-health counseling, but do not promote fasting regimens as a validated anti-aging therapy outside the context of registered clinical trials.", "Across 14 curated reference papers, the evidence base for Fasting shows a context-dependent profile. Negative signals appear in: contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Fasting anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "e64257d3-7980-4e68-9b2d-12e06cf91b11", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 14, "included": 14, "included_or_retained": 14, "screened": 14, "wording": "14 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "e64257d3-7980-4e68-9b2d-12e06cf91b11",
  "researka_submission_id": "7c5ccb76-8350-42ae-8ce7-2d6860416cf3",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/e64257d3-7980-4e68-9b2d-12e06cf91b11/sidecars/contradiction_map.json"
}